Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 71 articles: HTML format

Single Articles

June 2024
1. LAFAYETTE R, Kristensen J, Stone A, Barratt J, et al
   Targeted release of budesonide in primary IgA nephropathy - Authors' reply.
   Lancet. 2024;403:2786.
   PubMed    
   
   
   
2. ZOU Y, Du X, Zou J
   Targeted release of budesonide in primary IgA nephropathy.
   Lancet. 2024;403:2785-2786.
   PubMed    
   
   
   
3. HU Y, Zhang Y
   Targeted release of budesonide in primary IgA nephropathy.
   Lancet. 2024;403:2785.
   PubMed    
   
   
   
4. SAKUMA I, Ishibashi R, Matsue K, Vatner DF, et al
   Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man.
   Lancet. 2024;403:e33.
   PubMed    
   
   
   April 2024
5. HOI A, Igel T, Mok CC, Arnaud L, et al
   Systemic lupus erythematosus.
   Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398.
   PubMed     Abstract available
   
   
   
6. KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al
   CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
   Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424.
   PubMed    
   
   
   February 2024
7. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
   Diagnosis and management of ANCA-associated vasculitis.
   Lancet. 2024;403:683-698.
   PubMed     Abstract available
   
   
   
8. VAN DER HELM-VAN MIL AHM
   Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
   Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
   PubMed    
   
   
   January 2024
9. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
   Complement in human disease: approved and up-and-coming therapeutics.
   Lancet. 2024;403:392-405.
   PubMed     Abstract available
   
   
   
10. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    PubMed     Abstract available
    
    
    November 2023
11. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    PubMed     Abstract available
    
    
    
12. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    PubMed    
    
    
    
13. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    PubMed     Abstract available
    
    
    
14. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available
    
    
    October 2023
15. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available
    
    
    
16. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    PubMed     Abstract available
    
    
    
17. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    PubMed    
    
    
    September 2023
18. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    PubMed     Abstract available
    
    
    
19. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    PubMed    
    
    
    
20. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    PubMed     Abstract available
    
    
    August 2023
21. LAFAYETTE R, Kristensen J, Stone A, Floege J, et al
    Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lancet. 2023 Aug 14:S0140-6736(23)01554-4. doi: 10.1016/S0140-6736(23)01554.
    PubMed     Abstract available
    
    
    
22. HARALDSSON B
    Phase 3 trial results bring hope for patients with IgA nephropathy.
    Lancet. 2023 Aug 14:S0140-6736(23)01633-1. doi: 10.1016/S0140-6736(23)01633.
    PubMed    
    
    
    
23. RAMANAN AV, Quartier P, Okamoto N, Foeldvari I, et al
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023;402:555-570.
    PubMed     Abstract available
    
    
    July 2023
24. RIFE EC, Cron RQ
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Jul 6:S0140-6736(23)01134-0. doi: 10.1016/S0140-6736(23)01134.
    PubMed    
    
    
    June 2023
25. 
    Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    PubMed     Abstract available
    
    
    
26. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    PubMed    
    
    
    May 2023
27. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available
    
    
    
28. WEN X, Li B
    A population-based study on autoimmune disease.
    Lancet. 2023 May 5:S0140-6736(23)00621-9. doi: 10.1016/S0140-6736(23)00621.
    PubMed    
    
    
    April 2023
29. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    PubMed     Abstract available
    
    
    March 2023
30. LUNDBERG S, Bergen K
    We can go further in non-immunosuppressive treatment of IgA nephropathy.
    Lancet. 2023 Mar 31:S0140-6736(23)00630-X. doi: 10.1016/S0140-6736(23)00630.
    PubMed    
    
    
    
31. HEERSPINK HJL, Radhakrishnan J, Alpers CE, Barratt J, et al
    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Lancet. 2023 Mar 31:S0140-6736(23)00569-X. doi: 10.1016/S0140-6736(23)00569.
    PubMed     Abstract available
    
    
    
32. DURCAN L, Murphy G
    SLE-BRAVE I and II.
    Lancet. 2023;401:972-973.
    PubMed    
    
    
    
33. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    PubMed     Abstract available
    
    
    February 2023
34. PETRI M, Bruce IN, Dorner T, Tanaka Y, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Lancet. 2023 Feb 24:S0140-6736(22)02546-6. doi: 10.1016/S0140-6736(22)02546.
    PubMed     Abstract available
    
    
    
35. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    PubMed     Abstract available
    
    
    January 2023
36. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    PubMed     Abstract available
    
    
    
37. GUGER M, Ransmayr G, Sonnberger M, Hametner S, et al
    Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia.
    Lancet. 2023;401:226.
    PubMed    
    
    
    
38. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    PubMed    
    
    
    
39. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    PubMed    
    
    
    
40. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    PubMed    
    
    
    December 2022
41. HEBBINK JA, Nobels-Janssen E, Verhagen I, Kusters B, et al
    Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome.
    Lancet. 2022;400:1966.
    PubMed    
    
    
    October 2022
42. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    PubMed    
    
    
    August 2022
43. RIDKER PM
    Autoimmune diseases and atherothrombotic risk.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.
    PubMed    
    
    
    
44. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    PubMed     Abstract available
    
    
    May 2022
45. RUPERTO N, Brunner HI, Posner HB, Lazariciu I, et al
    Tofacitinib for juvenile idiopathic arthritis - Authors' reply.
    Lancet. 2022;399:1866.
    PubMed    
    
    
    
46. MURRAY GM, Renton WD
    Tofacitinib for juvenile idiopathic arthritis.
    Lancet. 2022;399:1865-1866.
    PubMed    
    
    
    April 2022
47. SETHI S, De Vriese AS, Fervenza FC
    Acute glomerulonephritis.
    Lancet. 2022;399:1646-1663.
    PubMed     Abstract available
    
    
    
48. PRASAD A
    Angela Migowa: advocating for children with rheumatic diseases.
    Lancet. 2022;399:1294.
    PubMed    
    
    
    March 2022
49. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    PubMed    
    
    
    January 2022
50. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    PubMed    
    
    
    November 2021
51. CLARKE SLN, Ramanan AV
    Tofacitinib in juvenile idiopathic arthritis.
    Lancet. 2021;398:1943-1945.
    PubMed    
    
    
    
52. RUPERTO N, Brunner HI, Synoverska O, Ting TV, et al
    Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Lancet. 2021;398:1984-1996.
    PubMed     Abstract available
    
    
    
53. LODGE FM, Moody WE, Tosounidou S, Chue CD, et al
    Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
    Lancet. 2021;398:1913.
    PubMed    
    
    
    
54. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    PubMed     Abstract available
    
    
    
55. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    PubMed    
    
    
    
56. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    PubMed    
    
    
    
57. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    PubMed    
    
    
    October 2021
58. CHEN LYC, Slack GW, Carruthers MN
    IgG4-related disease and Rosai-Dorfman-Destombes disease.
    Lancet. 2021;398:1213-1214.
    PubMed    
    
    
    
59. EMILE JF, Vaglio A, Cohen-Aubart F, Haroche J, et al
    IgG4-related disease and Rosai-Dorfman-Destombes disease - Authors' reply.
    Lancet. 2021;398:1214-1215.
    PubMed    
    
    
    August 2021
60. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    PubMed     Abstract available
    
    
    July 2021
61. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    PubMed    
    
    
    
62. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.
    PubMed    
    
    
    June 2021
63. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed     Abstract available
    
    
    
64. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    PubMed    
    
    
    
65. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.
    PubMed    
    
    
    
66. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    PubMed     Abstract available
    
    
    May 2021
67. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    PubMed     Abstract available
    
    
    
68. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.
    PubMed    
    
    
    April 2021
69. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    PubMed    
    
    
    
70. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    PubMed    
    
    
    October 2020
71. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.